Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

29 Oct 2021

Abstract excerpt

Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34716452
DOI: 10.1038/s41590-021-01068-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsPMID 34716452Read ↗

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitopeSemantic proximity Read ↗

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinSemantic proximity Read ↗

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsSemantic proximity Read ↗

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humansSemantic proximity Read ↗

Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal AntibodiesSemantic proximity Read ↗

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 miceSemantic proximity Read ↗

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variantsSemantic proximity Read ↗

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodiesSemantic proximity Read ↗

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainSemantic proximity Read ↗

A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variantsSemantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.